Monoclonal Antibody Development Targeting IL-23 for Autoimmune Diseases

Creative Biolabs has organized a staff of outstanding scientists who have engaged in drug development for autoimmune diseases. Cytokines always play a pivotal role in the establishment and maintenance of autoimmune diseases. Interleukin (IL)-23 is a key target for the efficient treatment of autoimmune diseases. Creative Biolabs is committed to providing overall solutions for anti-IL23 monoclonal antibody (mAb) development to facilitate our clients' research in autoimmune disease.

IL23: A Drug Target for Autoimmune Diseases

IL-23, a member of the IL-12 cytokine family, is a heterodimeric cytokine composed of IL-12p40 subunit and p19 subunit. IL-23 is mainly secreted by activated macrophages and dendritic cells located in peripheral tissues as a disulfide-linked complex with the polypeptide p19 binding protein p40. IL-23 is a central proinflammatory cytokine with a wide range of influence over immune response. It represents one of the most significant human genetic polymorphisms in autoimmunity including ankylosing spondylitis, psoriasis, sarcoidosis, multiple sclerosis (MS), and inflammatory bowel diseases. Meanwhile, IL-23 was sufficiently indicated acting as a maturation factor for Th17 cells, which had just been discovered and identified as the main player in autoimmunity. Although similar to IL-12 both structurally and in the ability of memory T cells to increase interferon-γ (IFN-γ) production and proliferation, the ability of IL-23 to induce IL-17 provides a unique role compared with that of IL-12 in both the development and the maintenance of autoimmune inflammation. All these make IL-23 a key target of autoimmune disease therapy.

Fig.1 IL-23 signaling pathway. (Di, 2009)

Antibodies Targeting IL-23 for the Treatment of Autoimmune Diseases

Preventing IL-23 binding to its receptor (IL-23R) via mAb is an efficient autoimmune treatment targeting IL-23. Therapeutic agents targeting IL-23 have been proven to be very effective in autoimmune diseases, such as psoriasis. Some are already in the therapeutic armamentarium and others are in development. Therapeutic mAbs target IL-23 include but are not limited to anti-IL-12/IL-23 p40 antibodies and anti-IL-23p19 antibodies.

mAb Development Targeting IL-23 at Creative Biolabs

As a pioneer and the undisrupted global leader in antibody discovery and development, Creative Biolabs has established cutting-edge platforms for antibody development, including antigen-specific B lymphocytes sorting platform, hybridoma platform, and phage display platform. Our scientists have perfected our technical pipelines for anti-IL-23 antibody development. Moreover, we have gained extensive experience in antibody affinity maturation by oligonucleotide-directed mutagenesis and phage display antibody library screening.

Highlights of Monoclonal Antibody Development Targeting IL-23

• Tailored strategies for anti-IL-23 antibody development
• Antibody with high sensitivity and high affinity
• Top-rated customer experience
• Reliability and information security

With Ph.D.-level scientists and over 10 years' experience in mAb development for autoimmune diseases, Creative Biolabs is dedicated to offering high-quality custom services in anti-IL-23 antibody development projects to meet our clients' R&D timeline and budget. If you are interested in anti-IL-23 antibody discovery and development, please contact us for more information and a detailed quote.

References

1. Di Cesare, A.; et al. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology. 2009, 129(6):1339-50.
2. SAKKAS, L.I.; et al. New treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Frontiers in pharmacology. 2019, 10:872.

For Research Use Only | Not For Clinical Use